Unmet needs and opportunities, treatment options, pipeline assessment, R&D strategies, outlook

company logo

Dublin, June 10, 2022 (GLOBE NEWSWIRE) — The “Report on Alpha-1 Antitrypsin Deficiency Market Size and Trends, Including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and forecast, 2021-2031” drug pipelines have been added to from ResearchAndMarkets.com offer.

The 2MM market (USA and Germany) is expected to grow from $1.2 billion in 2021 to $3.48 billion in 2031 at a CAGR of 11.2%. The introduction of 4 new pipeline agents are the major drivers for this market growth.

Alpha-1 antitrypsin deficiency (AATD) is an inherited condition that leads to an increased risk of chronic obstructive pulmonary disease (COPD), liver failure, skin problems (panniculitis) and inflammation of blood vessels (vasculitis) .

Current treatment options for AATD are alpha-1 proteinase inhibitor (A1-PI) therapies, which provide alpha-1 antitrypsin (AAT) protein that prevents the overproduction of elastase in lung tissue.

The forecasts cover three periods: base year, 5 years and 10 years

  • AATD prevalence is increasing at a steady rate, in line with population growth in 2MM at a TGA of 1.07%

  • Currently, the treatment regimen for AATD in 2MM is entirely limited to the four marketed alpha-1 proteinase inhibitors

  • There are several unmet needs in this space, including the need for early diagnosis of AATD and new therapies with improved efficacy.

  • AATD’s late-stage R&D pipeline focuses on the development of novel AI-PI therapy, NE inhibitors and RNAi therapies

  • Significant growth is expected throughout the forecast period as the AATD population steadily increases and new therapies enter the market

Scope

  • Overview of AATD, including epidemiology, symptoms, diagnosis, and disease management

  • AATD Therapies Market Annualized Revenue, Annual Therapy Cost and Treatment Utilization Pattern in 2021 and Ten-Year Forecast to 2031

  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AATD therapies market

  • Pipeline analysis, comprehensive data assessing emerging trends and mechanisms of action being developed for the treatment of AATD. The most promising candidates in late-stage development are profiled

  • Analysis of the current and future competition in the global AATD therapeutics market. In-depth review of key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications

Main topics covered:

1. Summary
1.1 Executive Summary

2 Overview of the disease
2.1 Overview of Alpha-1 Antitrypsin Deficiency (AATD)
2.2 AATD SWOT Analysis
2.3 Classification of AATDs

3 Epidemiology
3.1 Prevalent diagnosed cases of alpha-1 antitrypsin deficiency, males and females, 2021-31
3.2 Sources and methodology

4 current treatment options
4.1 Treatment Paradigm
4.2 Marketed products
4.3 Product Profiles: Alpha-1 Proteinase Inhibitors (Glassia, Prolastin-C, Zemaira/Respreeza, Aralast NP)

5 Unmet needs and opportunities
5.1 Unmet need for AATD
5.2 Previous diagnosis of AATD disease
5.3 AATD treatments with improved efficacy
5.4 Reduced cost for AATD treatments
5.5 Dosage of treatment for AATD patients
5.6 Patient compliance

6 Pipeline assessment
6.1 AATD Pipeline Overview
6.2 Main pipeline agents
6.3 Product Profiles: Second Generation Alpha-1 Proteinase Inhibitor (Human), PHP-303, Alvelestat, Belcesiran, ARO-AAT (Fazirsiran Sodium)
6.4 Pipeline Products – Revise Designations
6.5 AATD: Overview of Clinical Trials (Phase II/III)

7 R&D strategies
7.1 Trends in clinical trial design in AATD
7.2 Trading Trends in the AATD

8 Market Outlook
8.1 AATD Sales Forecast
8.2 AATD Market Forecast
8.3 Market Drivers and Barriers

9 Appendix

For more information on this Drug Pipelines report, visit https://www.researchandmarkets.com/r/58fksg

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Comments are closed.